ArticleHaematologica2020
CRISPR/Cas9-mediated
Open access · goldAbstract read
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 58 citations in OpenAlex.
- CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Beyond the Human Body: Models for Studying Neutrophil Biology.Immunology and cell biology · 2026Review
- The multidimensional signaling of ELANE: from congenital hematopoietic failure to immune microenvironment crosstalk and targeted interventions.Cell communication and signaling : CCS · 2026Review
- Modeling myeloid cell development in health and disease using induced pluripotent stem cells.Frontiers in immunology · 2026Review
- Targeted inhibition ofMolecular therapy. Methods & clinical development · 2025Article
- CRISPR-based therapeutic genome editing for inherited blood disorders.Nature reviews. Drug discovery · 2025Review
- Precision T cell correction platform for inborn errors of immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- HAX1 inhibits apoptosis and promotes maturation of neutrophils.Cell communication and signaling : CCS · 2025Article
- Flavopiridol restores granulopoiesis in experimental models of severe congenital neutropenia.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Article
- Case Report: Heterozygous out-of-frame frameshift variant inFrontiers in immunology · 2025Article
- G-CSF resistance of ELANE-mutant neutropenia depends on SERF1-containing truncated-neutrophil elastase aggregates.The Journal of clinical investigation · 2024Article
- Article
- Comparison of Gene-Editing Approaches for Severe Congenital Neutropenia-Causing Mutations in theThe CRISPR journal · 2024Article
- CRISPR-Cas9n-mediated ELANE promoter editing for gene therapy of severe congenital neutropenia.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Neutrophils cultured ex vivo from CD34Journal of translational medicine · 2024Article
- Review
- Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies forJournal of cellular immunology · 2024Article
- Mutant allele knockout with novel CRISPR nuclease promotes myelopoiesis in ELANE neutropenia.Molecular therapy. Methods & clinical development · 2022Article
- Comparison of Gene Editing versus a Neutrophil Elastase Inhibitor as Potential Therapies forJournal of cellular immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 2 countries.
Masoud NasriDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Malte RitterDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Perihan MirDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Benjamin DannenmannDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Narges AghaallaeiDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Diana AmendDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Vahagn MakaryanDepartment of Medicine, University of Washington, Seattle, WA, USA.
Yun XuDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Breanna FletcherDepartment of Medicine, University of Washington, Seattle, WA, USA.
Regine BernhardDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Ingeborg SteiertDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Karin HahnelDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Jürgen BergerMax Planck Institute for Developmental Biology, Tübingen, Germany.
Iris KochMax Planck Institute for Developmental Biology, Tübingen, Germany.
Brigitte SailerMax Planck Institute for Developmental Biology, Tübingen, Germany.
Katharina HippMax Planck Institute for Developmental Biology, Tübingen, Germany.
Cornelia ZeidlerDepartment of Oncology, Hematology, Immunology and Bone Marrow Transplantation, Hannover Medical School, Hannover, Germany.
Maksim KlimiankouDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Baubak BajoghliDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
David C DaleDepartment of Medicine, University of Washington, Seattle, WA, USA.
Karl WelteDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany.
Julia SkokowaDepartment of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany Julia.Skokowa@med.uni-tuebingen.de.
University Children's Hospital Tübingen · DEMax Planck Institute for Developmental Biology · DEUniversity of Washington · USMedizinische Hochschule Hannover · DE
Funding
Severe Chronic Neutropenia International RegistryR24AI049393 · NIAID · UNIVERSITY OF WASHINGTON · PI DALE, DAVID CHANDLER · 2004 to 2019
$10.6MGene Editing vs Neutrophil Elastase Inhibitors for Treatment of ELANE Associated NeutropeniaR01HL151629 · NHLBI · UNIVERSITY OF WASHINGTON · PI DALE, DAVID CHANDLER · 2020 to 2022
$1.8MNHLBI NIH HHS R01 HL151629NIAID NIH HHS R24 AI049393
Abstract
A Autosomal-dominant
Indexed as
Hematopoietic Stem Cell TransplantationInduced Pluripotent Stem CellsNeutropeniaCongenital Bone Marrow Failure SyndromesCRISPR-Cas SystemsHumansMutation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.